- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02365467
Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Descending TAA and Chronic Dissections
Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Descending Thoracic Aortic Aneurysms and Chronic Dissections
The purpose of the Feasibility study is to characterize the safety of the Valiant Mona LSA Thoracic Stent Graft System, including an assessment of the safety and effectiveness of the device acutely and at the 30 day visit in the identified subject population. This study will also evaluate the current instructions for use and may direct changes to the delivery and deployment steps.
The purpose of the expansion to the Feasibility Study is to characterize the Valiant Mona LSA Thoracic Stent Graft System, in particular to assess the safety and effectiveness of the device acutely and at the 30 day visit, in subjects enrolled with chronic, Type B dissections.
Study Overview
Status
Intervention / Treatment
Detailed Description
The purpose of the clinical investigation is to assess the feasibility of the Valiant Mona LSA Thoracic Stent Graft System to repair fusiform/saccular aneurysms, penetrating ulcers and chronic type B dissections of the DTA in patients who require coverage of the LSA, including an assessment of the safety and effectiveness of the device acutely and at the 30 day visit in the identified subject population. Procedural information will be collected in order to enhance the current instructions for use and delivery and deployment steps.
The chronic Type B Dissection expansion subjects will be prospectively enrolled in support of a future premarket approval analysis for the Valiant Mona LSA device.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for Thoracic Aortic Aneurysms and Penetrating Ulcers:
- Subject is at least 18 years of age.
- Subject understands and has signed an Informed Consent approved by the Sponsor and by the IRB for this study.
- Subject must be considered a candidate for revascularization of the LSA. Subject must be able to tolerate a surgical revascularization of the LSA.
Subject has a TAA/PAU which will require coverage of the LSA and is:
- a fusiform aneurysm with a diameter of ≥ 5.5 cm OR is > 2 times the diameter of the non-aneurysmal thoracic aorta; AND/OR
- a saccular aneurysm or PAU (ulcer defined as ≥ 10 mm in depth and 20 mm in diameter, or symptomatic)
- Subject has a healthy, non-diseased aortic proximal seal zone of at least 20 mm from the distal end of the LCC ostium to the beginning of the disease, including at least 10 mm between the LSA and the LCC.
- Subject has a non -diseased aortic proximal neck length of >0mm distal to the LSA
- Subject has a non-diseased aortic diameter between 25 mm and 42 mm
- Subject has a non-diseased LSA with a diameter between 8 mm and 13 mm.
- Subject has sufficient landing zone within the LSA to accommodate the BSG without occlusion of any significant vessels
Brachial, iliac or femoral artery access vessel morphology (diameter, calcification, tortuosity) that is compatible with vascular access techniques, the device, or accessories.
- Introducer sheath is required for all procedures.
- An iliac conduit is required for access if the above requirements are not met.
Inclusion Criteria for Chronic Type B Dissections:
- Subject is at least 18 years of age.
- Subject understands and has signed an Informed Consent approved by the Sponsor and by the IRB for this study.
- Subject must be considered a candidate for revascularization of the Left Subclavian Artery (LSA). Subject must be able to tolerate a surgical revascularization of the LSA.
- Subject has a chronic type B dissection which will require coverage of the LSA. A chronic type B dissection is defined as > 30 days from symptom onset and is complicated with an aortic diameter ≥ 5.5 cm or has progressive aortic enlargement (> 5 mm/year).
- Subject has a healthy, non-diseased aortic proximal seal zone of at least 20 mm from the distal end of the LCC ostium to the beginning of the disease, including at least 10 mm between the LSA and the LCC
- Subject has a non-diseased aortic diameter between 28 mm to 44 mm.
- Subject has a non-diseased LSA with a diameter between 8 mm and 13 mm.
- Subject has sufficient landing zone within the LSA to accommodate the BSG without occlusion of any significant vessels
Brachial, iliac or femoral artery access vessel morphology (diameter, calcification, tortuosity) that is compatible with vascular access techniques, the device, or accessories.
- Introducer sheath is required for all procedures.
- An iliac conduit is required for access if these requirements are not met.
Exclusion Criteria
Subjects will be excluded if they have conditions requiring prospective revascularization of the LSA including:
- Dominant left vertebral artery requiring revascularization
- Prior coronary artery bypass graft utilizing the left mammary artery requiring revascularization
- Incomplete circle of Willis or other neurological vasculature requiring revascularization
- Subject has an aneurysmal, tortuous, or atherosclerotic LSA.
- Subject has an acute dissection of the descending thoracic aorta.
- Subject has an intramural hematoma of the descending thoracic aorta.
- Subject has prohibitive calcification, occlusive disease, or tortuosity of intended fixation sites.
- Subject has circumferential calcification in the external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 10mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned.
- Subject requiring an aortic conduit or direct aortic access
- Subject has an aortic atheroma classified as grade IV or grade V.
- Subject has had previous endovascular repair of the ascending and/or descending thoracic aorta <30 days of implantation of investigational device or previous repair was a non-Medtronic device
- Treatment with the Valiant Mona LSA Thoracic Stent Graft system would require intentional coverage of the left common carotid artery with the stent graft fabric.
- Subject has significant and/or circumferential aortic mural thrombus at either the proximal or distal attachment sites that would compromise fixation and seal of the device.
- Subject is a pregnant female.
- Subject has a known allergy or intolerance to the device components.
- Subject is in acute renal failure or has renal insufficiency with a serum creatinine ≥ 2.0 mg/dL or is on dialysis.
- Subject has a body habitus which prevents adequate visualization of the aorta.
- Subject has coronary artery disease with unstable angina and who has not received treatment.
- Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration).
- Subject has active systemic infection and/or a mycotic aneurysm.
- Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observations of this study.
- Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures.
- Subject has a life expectancy of less than 1 year.
- Subject requires treatment of an infrarenal aneurysm at the time of the implantation.
- Subject has had previous surgical or endovascular treatment of an infra-renal aortic aneurysm <30 days of implantation of investigational device.
- Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion.
- Subject has had a cerebral vascular accident (CVA) within 3 months.
- Subject has had a myocardial infarction (MI) within 3 months.
- Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment with Valiant Mona LSA device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
30 Day Composite Safety Endpoint
Time Frame: 1 month
|
Within 1 month (Day 0 - Day 30) from the index procedure, composite endpoint consisting of:
|
1 month
|
30 Day Treatment Success
Time Frame: 1 month
|
Treatment success which is defined as technical success (the successful delivery and deployment of the Valiant Mona LSA Thoracic Stent Graft System in the planned location with no unintentional coverage of other vessels, assessed intra-operatively, and the removal of the delivery system) and successful exclusion of the aneurysm or false lumen while maintaining patency of the Main Stent Graft and Branch Stent Graft at 30 day visit.
This endpoint is site reported.
|
1 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10151194DOC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Aneurysm, Thoracic, Chronic Type B Dissection
-
University of PennsylvaniaBolton MedicalEnrolling by invitationThoracic Aortic Aneurysm | Thoracic Aortic Dissection | MicroemboliUnited States
-
The University of Texas Health Science Center,...RecruitingACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy (ACUTE-B)Distal Aortic Dissection | Dissection, Aortic Acute | Acute Type B Aortic Dissection (Uncomplicated)United States
-
Petrovsky National Research Centre of SurgeryRecruitingThoracic Aortic Aneurysm | Thoracic Aortic Dissection | Cardiac Valve Disease | Aortic Aneurysm and DissectionRussian Federation
-
Hangzhou Endonom Medtech Co., Ltd.CompletedAortic Dissection Type BChina
-
Meshalkin Research Institute of Pathology of CirculationUnknownAortic Dissection Type B
-
Rodney A. White, M.D.CompletedThoracic Aortic Dissection | Intramural Hematoma | Thoracic Aortic Aneurysms | Pseudoaneurysm | Thoracic TransectionsUnited States
-
Yonsei UniversityWithdrawn
-
JOTEC GmbHCompletedType B Aortic DissectionGermany, Spain, Poland, Italy
-
University Hospital, CaenUnknown
-
CryoLife EuropaCompletedThoracic Aortic Aneurysm | Aortic Valve Replacement | Type A Aortic Dissection | Cardiovascular ProceduresGermany, Italy
Clinical Trials on Valiant Mona LSA Thoracic Stent Graft System
-
Medtronic CardiovascularCompletedThoracic Aortic AneurysmsUnited States, United Kingdom
-
University Hospital, ToulouseMedtronic VascularWithdrawnAortic Aneurysm, ThoracicFrance
-
Medtronic CardiovascularCompletedThoracic Aortic AneurysmUnited States
-
Medtronic CardiovascularNAMSAActive, not recruitingThoracic Aortic DissectionUnited States, Korea, Republic of, Netherlands, Denmark, New Zealand, Thailand, Japan, Slovakia, Greece, Italy
-
Medtronic CardiovascularCompletedAortic Aneurysm, ThoracicNetherlands, Denmark, United Kingdom, France, Canada, Italy
-
Medtronic CardiovascularCompleted
-
Medtronic CardiovascularMedtronicCompleted
-
Medtronic CardiovascularMedtronicCompletedBlunt Thoracic Aortic InjuryUnited States, Canada
-
NYU Langone HealthCompletedThoracoabdominal Aortic AneurysmsUnited States
-
Matthew EagletonMedtronic; NAMSA; Sanford HealthActive, not recruitingThoracoabdominal Aortic AneurysmUnited States